This page is updated frequently with new G Protein-related patent applications.
|| List of recent G Protein-related patents
|Methods for controlling fucosylation levels in proteins|
The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions..
Center Of Molecular Immunology
|Novel genes involved in biosynthesis|
The invention provides a novel myb class transcription factor gene (nucleic acid sequences, protein sequences, and variants and fragments thereof) designated myb14 by the applicants, that is useful for manipulating the production of flavonoids, specifically condensed tannins, in plants. The invention provides the isolated nucleic acid molecules encoding proteins with at least 70% identity to any one of myb14 polypeptide sequences of seq id no: 14 and 46 to 54.
Grasslanz Technology Limited
|Oncostatin m receptor antigen binding proteins|
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins. E.g., antibodies and functional fragments, derivatives, muteins, and variants thereof.
Biogen Ma Inc.
|Method for refining protein including self-cutting cassette and use thereof|
The present invention relates to a self-cleaving fusion protein including a target protein, a peptide consisting of amino acid sequence represented by lpxtg, a domain of sortase a having cleaving function, and a tag, which are sequentially positioned from the amino terminal; a nucleic acid encoding the same; an expression vector including the nucleic acid of the present invention; and a cell transformed with the expression vector of the present invention. In addition, the present invention relates to a method for refining a target protein including culturing, dissolving, and purifying the transformed cell, and a method for preparing a therapeutic antibody-drug conjugate by using the purifying method..
Scripps Korea Antibody Institute
|Il-1 family variants|
The present invention provides compositions and methods relating to il-1rrp2 requiring proteins.. .
|Thiazole inner salt compounds, and preparation methods and uses thereof|
The present invention pertains to field of pharmaceutical chemicals, and relates to thiazole inner salt compounds, preparation methods and uses thereof. Specifically, the present invention relates to a compound of formula i, hydrates or pharmaceutically acceptable salts thereof.
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a. China
|Methods of treating pain using protein solutions|
Methods and compositions for treating pain in mammalian subjects are provided. The methods include obtaining blood or a fraction of blood from the subject, measuring a therapeutic indicator in the blood or in the fraction blood, and administering an anti-inflammatory composition to the subject if the therapeutic indicator is equal to or above a threshold level.
|Method for producing autologous proteins|
A method of introducing proteins to a patient is provided for treating a wide variety of diseases. The method includes collecting blood from a patient's vein.
|Computer-implemented methods of determining protein viscosity|
The invention provides computer-implemented methods for screening proteins such as antibodies based on viscosity properties. The methods involve making a spatial charge map (scm) of the three-dimensional structure of the antibody or protein and determine a scm score depending on a condition such as e.g.
Novartis Pharma Ag
|Novel antigen binding protein and its use as addressing product for the treatment of cancer|
The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to axl and, by inducing internalization of axl, being internalized into the cell.
Pierre Fabre Medicament
Thermophilic and thermoacidophilic glycosylation genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for glycosylating and/or post-translationally modifying proteins using isolated and/or purified polypeptides and nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc.
Rhamm, a co-receptor and its interactions with other receptors in cancer cell motility and the identification of cancer prognitor cell populations
Cd44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (cd168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors.
The Regents Of The University Of California
Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
Disclosed herein are methods for the isolation and purification of anti-il-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., protein a affinity chromatography), ion exchange chromatography, and hydrophobic chromatography.
Antibodies to human signal peptide-containing proteins
The invention provides a human signal peptide-containing proteins (sigp) and polynucleotides which identify and encode sigp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Cmv neutralizing antigen binding proteins
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (cmv). Also encompassed by the invention are antigen binding proteins that have been humanized.
Board Of Regents Of The University Of Texas System
Treatment and prevention of malaria
There are provided antigens, vectors encoding the antigens, and antibodies and other binding compounds to the antigens and uses thereof in the prevention or treatment of malaria. In particular, compositions are provided comprising a reticulocyte-binding protein homologue 5 (pfrh5) antigen having at least 90% identity with seq id no: 1, or a fragment thereof; or which comprise a viral vector that expresses pfrh5 antigen having at least 90% identity with seq id no: 2, or a fragment thereof..
Isis Innovation Limited
Interferon lambda-antibody complexes
The present invention concerns methods and compositions for forming complexes of interferon-λ with an antibody or antigen-binding antibody fragment. In preferred embodiments, the interferon-λ and the antibody or fragment are fusion proteins, each comprising a dimerization and docking domain (ddd) moiety from human protein kinase a or an anchor domain (ad) moiety from an a-kinase anchoring protein (akap).
Ibc Pharmaceuticals, Inc.
Muscle preservation in overweight or obese adult during weight loss program
The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin d, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult..
Palatable foods for a methionine-restricted diet
A method is disclosed for making palatable methionine-restricted foods, to deliver a methionine-restricted diet to human or veterinary patients. A protein or a food product containing protein is partially oxidized, preferably with ozone, to oxidize nearly all of the methionine and cysteine.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
Method for assessing protein identity and stability
The present invention relates to methods and other technologies that may be used to determine whether compositions (e.g., pharmaceutical compositions) comprising interleukin-10 molecules (e.g., pegylated interleukin-10) meet particular product-related specifications prior to being administered to a subject for the treatment and/or prevention of the diseases, disorders and conditions, and/or the symptoms thereof, described herein.. .
Armo Biosciences, Inc.
Cyclic-di-amp specific detection
The present disclosure provides a simple yet fast, cost effective, reliable method for the detection and quantification of cyclic-di-adenosine monophosphate (c-di-amp) by measuring c-di-amp binding to a c-di-amp-binding protein (cabp). A sample is contacted with cabp in the presence of biotin-labeled c-di-amp.
Albany Medical College
Modified membrane spanning proteins and methods for the preparation and use thereof
In accordance with the present invention, there are provided functionally modulated tool receptors which are useful for drug discovery and development. In certain aspects and embodiments as described herein, a sophisticated and powerful approach has been designed that allows the rapid development of enhanced receptors, while simultaneously exploring millions of possibilities for improved properties with respect to such properties as protein expression, homogeneity, stabilization, conformational and activation pathway selectivity, antigenicity, immunogenicity, and the like.
Abilita Bio, Inc.
Method of screening for chaperonin modulator
The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as alzheimer's disease, parkinson's disease and huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target.
Postech Academy-industry Foundation
Chemically modified sophorolipids and uses thereof
The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture.
Sophoro Biotechnologies, Llc
Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant dll4 and/or vegf expression or activity.. .
Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), wherein the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
Polypeptides for use in self-assembling protein nanostructures
Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using such synthetic nanostructures are disclosed herein.. .
University Of Washington
Methods of increasing protein purity using protein a based chromatography
The present invention provides methods for increasing purity of an fc-containing protein by removing protein aggregates during the protein a chromatography step used during the purification of the fc-containing protein.. .
Emd Millipore Corporation
Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including mps1 (ttk), erk5 (bmk1, mapk7), polo kinase 1, 2, 3, or 4, ack1, ack2, abl, dcamkl1, abl1, abl mutants, dcamkl2, ark5, brk, mknk2, fgfr4, tnk1, plk1, ulk2, plk4, prkd1, prkd2, prkd3, ros1, rps6ka6, taok1, taok3, tnk2, bcr-abl, gak, csrc, tpr-met, tie2, met, fgfr3, aurora, axl, bmx, btk, c-kit, chk2, flt3, mst2, p70s6k, pdgfr, pkb, pkc, raf, rock-h, rsk1, sgk, trka, trkb and trkc, and the use of such compounds in the treatment of various diseases, disorders or conditions.. .
Dana-farber Cancer Institute, Inc.
Treatment of merkel cell polyomavirus infection
The present disclosure provides novel compositions and methods for treating an infection of the skin resulting from an infection of a member of the orthopolyomavirus virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus.
Ansun Biopharma, Inc.
Lung injury repair compositions and methods
The present invention provides a pharmaceutical composition comprising protein kinase c zeta (pkc-ζ) inhibitor and therapeutic methods for preventing or treating a pathological condition or symptom or for inducing proliferation of lung progenitor cells in a mammal by administering the pkc-ζ inhibitor.. .
University Of Iowa Research Foundation
Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, whom is affected by a dendritic spine defect caused by the impairment in neurofibromin (nf1 protein), valosin-containing protein (vcp), atlastin-1 (atl1), or superoxide dismutase 1 (sod1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in nf1, vcp, atl1, or sod1..
Method for preparing protein cage, and in situ preparing hydrophobic additive-supported core-shell structured polymer-protein particles
The present invention relates to a method for preparing a protein cage which comprises: a 1st step of preparing an amphiphilic polymer comprising a 1st hydrophobic polymer and a 1st hydrophilic functional group; a 2nd step of preparing a hydrophilic protein comprising a 2nd functional group binding to the 1st functional group; a 3rd step of forming an amphiphilic polymer-protein hybrid by the binding of the 1st functional group and the 2nd functional group, and forming core-shell structured particles comprising a protein shell and an amphiphilic polymer core by the self-assembly of the amphiphilic polymer in a hydrophilic solvent; and a fourth step of removing some or all of the hydrophobic polymer of the core part from the core-shell structured particles.. .
Gachon University Of Industry-academic Cooperation Foundation
Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitor.
Regeneron Pharmaceuticals, Inc.
Compositions and methods for regulating angiogenesis and cholesterol and treating dyslipidemia, atherosclerosis, cancer and inflammatory conditions
The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of apoa-1 binding protein (apoaibp, aibp, or ai-bp), and methods for making and using them. In alternative embodiments, apoaibp-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia.
The Regents Of The University Of California
Colorimetric and fluorescent proteins
The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.. .
Board Of Trustees Of Michigan State University
Composition for stabilizing protein and pharmaceutical formulation comprising the same
The present invention relates to a composition for stabilizing tnfα-binding protein exhibiting physiological activity, and more specifically, to a composition for stabilizing protein including basic amino acid and sugar and/or ammonium salt, a pharmaceutical formulation including the same, and a method for stabilizing tnfα-binding protein. The formulation including basic amino acid; and sugar and/or ammonium salt according to the present invention effectively inhibits aggregation, denaturation and oxidation of tnfα-binding protein used for treating various diseases, for example, an anti-tnf-alpha antibody, such that the protein is capable of being preserved and stored for a long time, which is widely usable and effective in a medical field using tnfα-binding protein, for example, an anti-tnf-alpha antibody..
Discovery of fda-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
Using molecular docking screening, a few therapeutical compounds including trovafloxacin and levofloxacin have been first identified as potential inhibitors of fatty acid binding protein 4 (fabp4). The present invention provides a novel use of levofloxacin as an inhibitor of fabp4 and a drug for the treatment of metabolic diseases or a cardiovascular diseases.
The Chinese University Of Hong Kong
Method and pairing music and food selections
A system and method enable the selection of musical recordings for pairing with a food serving, possibly an entrée, a dessert or a beverage, for the purpose of increasing the enjoyment of a given meal. A plurality of factors for specific meal components such as entree, including protein type, method of cooking, amount of spice, and type of sauce are used to determine a specific numerical value for a meal; dessert, including content of cacao, sweetener and content of sweetener, ambient temperature at service and dairy content; and beverage, including but not limited to alcohol content, acidity, body, dryness, lingering quality, and ibu.
Method and pairing music and food selections
A system and method enable the selection of musical recordings for pairing with a food serving, possibly an appetizer, a main course, a dessert or a beverage, for the purpose of increasing the enjoyment of a given meal. A plurality of factors for specific meal components such as entree, including protein type, method of cooking, amount of spice, side dish component and type of sauce are used to determine a specific numerical value for a meal; appetizer including protein type, bread and dough content, method of cooking and spice level; dessert, including content of cacao, sweetener and content of sweetener, ambient temperature at service and dairy content; and beverage, including but not limited to alcohol content, acidity, body, dryness, lingering quality, and ibu.
Swath™ data-independent acquisition technology for the detection of host cell protein contaminants in biotherapeutics protein products
Systems and methods are provided for detecting host cell contaminants in a protein biotherapeutic product using sequential windowed acquisition tandem mass spectrometry. Sequential windowed acquisition is performed on a protein biotherapeutic product sample by sequentially stepping a precursor mass window across a mass range, fragmenting transmitted precursor ions of each stepped precursor mass window, and analyzing product ions produced from the fragmented transmitted precursor ions.
Method for producing stress tolerant transgenic plant by silencing a gene encoding calcium-dependent lipid-binding protein with c2 domain and applications of the same
A method for silencing rice plant, includes the steps of: identifying a first nucleotide sequence from oryza sativa, wherein the first nucleotide sequence is homologous to a ca2+-dependent lipid-binding gene of arabidopsis thaliana (atclb gene); cloning the first nucleotide sequence to a first vector to form a first recombinant vector, such that the first recombinant vector contains a first insert of the first nucleotide sequence; and transfer the first insert in the first recombinant vector to a second vector to form a second recombinant vector, such that the second recombinant vector contains a second insert of the first nucleotide sequence. The second recombinant vector, when being introduced to oryza sativa plant cells, is capable of silencing the first nucleotide sequence of the oryza sativa plant cells, such that the oryza sativa plant cells are tolerant to an abiotic stress..
Methods and compositions for wound treatment
The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.. .
Gep5 model for multiple myeloma
The invention provides, inter alia, methods of prognosing a subject with, or suspected of having, multiple myeloma. In certain embodiments, the methods entail testing the gene expression levels of enolase 1 (eno1), fatty acid binding protein 5 (fabp5), thyroid hormone receptor interactor 13 (trip 13), transgelin 2 (tagln2), and replication factor c (activator 1) 4 (rfc4) in a biological sample isolated from the subject.
Protein, manufacturing same, and evaluating protein activity
The present invention relates to a method for producing a protein, comprising an inspection process, wherein the inspection process comprises: a step of approximating an infrared absorption band derived from a protein appearing around 1500 to 1600 cm−1 or around 1600 to 1700 cm−1 in an infrared absorption spectrum of the protein, by one or more normal distributions, a step of calculating an index value indicating a degree of broadening of the infrared absorption band based on the normal distributions, and a step of comparing the index value with a predetermined threshold to select, as a good-quality product, a protein having a degree of broadening of the infrared absorption band that is smaller than the threshold.. .
Plasma kallikrein binding proteins
Plasma kallikrein binding proteins and methods of using such proteins are described.. .
Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of src homology 2-domain containing protein tyrosine phosphatase-2..
Anti-viral therapeutic for infection of the eye
The present disclosure provides novel compositions and methods for treating an infection of the eye resulting from an infection of a member of the picornavirdae virus family. In particular, the present disclosure provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by a pathogen, such as a virus.
Methods and compositions for promiting glucose homeostasis
A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (mkk3), mitogen-activated protein kinase kinase 6 (mkk4), mitogen-activated protein kinase kinase 6 (mkk6), p38 mitogen-activated protein kinase (p38mapk), mitogen-activated kinase-activated protein kinase 2 (mk2), or a combination thereof, in an effective amount to reduce blood glucose in a subject.
Electrochemiluminescence detecting an analyte in a liquid sample and analysis system
An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit.
Roche Diagnostics Operations, Inc.
Yeast promoters from pichia pastoris
In accordance with the invention, isolated nucleic acids, expression methods, host cells, expression vectors, and dna constructs for producing proteins, and proteins produced using the expression methods are described. More particularly, nucleic acids isolated from pichia pastoris wherein the nucleic acids have promoter activity are described.
Keck Graduate Institute Of Applied Life Sciences
Devices and methods for display of encoded peptides, polypeptides, and proteins on dna
A novel method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the dna encoding them. Proteins or peptides can be generated by in vitro translation of dna templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their dna templates.
The Board Of Trustees Of The Leland
Modulators of the eif2alpha pathway
Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eif2α phosphorylation, the integrated stress response (isr), and the unfolded protein response (upr); for treating diseases; for increasing protein production, and for improving long-term memory.. .
The Regents Of The University Of California
Dps fusion proteins for use in vaccines and diagnostics
Novel nanoparticle fusion proteins comprising proteins or peptides fused to dps (dna binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products.. .
Kj Biosciences Llc
Antimicrobial compositions and methods
The present invention is generally related to a product and process to reduce the microbial contamination on organic matter, such as processed meat, fruits and vegetables, plant parts, inanimate surfaces such as textiles and stainless steel, and in the mouth or on dental products. In particular, the invention is related to a product and process to disinfect surfaces using an antimicrobial composition containing an antimicrobial lipid, an enhancer selected from the group consisting of bacteriocins, antimicrobial enzymes, sugars, sugar alcohols, iron-binding proteins and derivatives thereof, siderophores, and combinations thereof, and optionally a surfactant..
3m Innovative Properties Company
Fibrosis biomarker assay
Methods of diagnosis or of quantitation of fibrosis are provided that comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of the measure in the patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a contacting protein fragments naturally present in the sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to the immunological binding partner to measure therein protein fragments comprising the neo-epitope.
Nordic Bioscience A/s
Binding proteins specific for insulin-like growth factors and uses thereof
Binding proteins, such as antibodies directed to igf-ii with cross-reactivity to igf-i and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the igf-ii with cross-reactivity to igf-i are disclosed.
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158p1d7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158p1d7 and variants thereof.. .
Modified biotin-binding protein, fusion proteins thereof and applications
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen.
Children's Medical Center Corporation
Antibody like protein
A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an fha domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the fha domain in non-conserved or non-structural sequences of the fha scaffold, and the library may also be in the form of a phagemid or phage library wherein the alp nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed alp protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural fha domain sequences.. .
Derivatisation of biological molecules
The polymers are particularly suitable for derivatising proteins, such as interferon-α.. .
Therapeutic compositions for neutralizing type i interferons, and methods of use
The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing type i interferons in a mammal. The compositions contain a soluble orthopoxvirus ifn-binding protein that is modified to remove the cell-binding region, and that specifically binds to type i ifns, and a pharmaceutically acceptable carrier or excipient.
The United States Of America As Represented By The Secretary Of The Army, Of Behalf Of The United
Compositions and methods for detecting s-nitrosylation and s-sulfinylation
The present invention relates to methods for detecting protein s-sulfinylation and s-sulfinylation within thiol groups in proteins, metabolites, or materials.. .
The Regents Of The University Of Michigan
Plant lectins as carriers of associated drug substances into animal and human cells
The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (b subunits) of plant “ab toxins” (ptb lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation.
Isolation and purification of antibodies using protein a affinity chromatography
Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise ph viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably protein a affinity, ion exchange chromatography, and hydrophobic chromatography.
Fused heterocyclic compounds as protein kinase inhibitors
The invention is fused heterocyclic compounds of formula (i), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including bruton's tyrosine kinase (btk), and for treating disorders mediated thereby..
Crystal structure of bifunctional transglycosylase pbp1b from e. coli and inhibitors thereof
The crystal structure at 2.16 Å resolution of the full-length bacterial bifunctional transglycosylase penicillin-binding protein 1b (pbp1b) from escherichia coli, in complex with its inhibitor moenomycin, is provided. The atomic coordinates of the complex as well as the moenomycin binding site are provided.
G Protein topics: Antibodies, Nucleic Acid, G Proteins, Nucleic Acids, Amino Acid, Polypeptide, Protein A Affinity Chromatography, Chromatography, Chromatograph, Liver Metastasis, Membrane Protein, Colorectal Carcinoma, Rectal Carcinoma, Prophylactic, Glycoprotein
Follow us on Twitter
This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.